Doxorubicin is a widely used chemotherapy agent, but its success in treating cancers is tempered by a known risk of heart muscle damage. Researchers at the Heidelberg Faculty of Medicine at Heidelberg University have been investigating ways to reduce that cardiac side effect.
Their work has now identified the molecular signaling pathway through which an existing cancer drug may protect the heart during doxorubicin treatment. The finding suggests that a drug already approved for cancer could be repurposed to help patients receiving this chemotherapy.
The source does not specify which drug or the exact pathway involved, so the details remain unclear. Still, pinpointing this mechanism offers a potential route toward safer doxorubicin regimens without compromising its anticancer effects.